AB Corporate Bond ETF (NASDAQ:EYEG) Short Interest Update

AB Corporate Bond ETF (NASDAQ:EYEG) was the target of a large drop in short interest during the month of June. As of June 15th, there was short interest totaling 100 shares, a drop of 34.6% from the May 31st total of 153 shares. Based on an average trading volume of 142 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.0% of the company’s shares are sold short.

Institutional Trading of AB Corporate Bond ETF

Several hedge funds have recently added to or reduced their stakes in EYEG. Kestra Advisory Services LLC acquired a new position in AB Corporate Bond ETF in the fourth quarter valued at about $34,000. Jane Street Group LLC bought a new stake in shares of AB Corporate Bond ETF in the second quarter worth about $232,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of AB Corporate Bond ETF by 32.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock worth $5,634,000 after purchasing an additional 38,685 shares during the period. Institutional investors and hedge funds own 64.16% of the company’s stock.

AB Corporate Bond ETF Stock Down 0.6%

Shares of NASDAQ:EYEG opened at $35.13 on Thursday. AB Corporate Bond ETF has a 52 week low of $34.82 and a 52 week high of $36.63. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.07. The company has a market capitalization of $28.10 million, a PE ratio of -20.91 and a beta of 0.17. The company has a 50 day moving average price of $35.23 and a two-hundred day moving average price of $35.52.

AB Corporate Bond ETF Cuts Dividend

The company also recently disclosed a monthly dividend, which will be paid on Tuesday, July 7th. Investors of record on Wednesday, July 1st will be given a $0.1358 dividend. The ex-dividend date is Wednesday, July 1st. This represents a c) dividend on an annualized basis and a dividend yield of 4.6%. AB Corporate Bond ETF’s dividend payout ratio is currently -102.98%.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.